Reason reviews the research behind One Skin's senotherapeutic skin-care spray

06-Nov-2020

Key points from article :

OneSkin launched a cosmetic product claimed to reduce levels of senescent cells in aged skin. The product contains a peptide 14 (OS-01) and decapeptide-52. The use of OS-01 is similar to topical application of rapamycin. Though no direct destruction occurs but a reduction in senescent cell creation and activity is seen. This allows existing processes of senescent cell clearance to catch up in aged skin. OS-01 performs better than rapamycin in reducing markers of cellular senescence. Formal trials and resulting human data are pending - though the product is available for anyone who wants to give it a try. Peptide 14 decreased human dermal fibroblasts (HDF) senescence induced by Hutchinson-Gilford Progeria (HGPS), chronological ageing, UV-B radiation, etc. It promoted skin health, reduced senescent cell markers and biological age of samples. It outperformed retinol treatment, the current gold-standard in "anti-aging" skin care. Research by OneSkin published in Biorxiv.